FCGR3A and neoplasm: Additionally, therapeutic strategies that combine the adoptive transfer of allogeneic memory NK cell with tumor-targeting mAb administration could take advantage of the skewed repertoire of KIR expressed by memory NK cells, with the aim to select donor/recipient combinations that would lower the interference of MHC-I-specific inhibitory receptors on CD16-dependent activation [250].